Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era

[1]  Deepali Kumar,et al.  Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave , 2022, American Journal of Transplantation.

[2]  J. Gottlieb,et al.  Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study , 2022, Infection.

[3]  P. Merville,et al.  COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders , 2022, Kidney International.

[4]  L. Braun-Parvez,et al.  Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients , 2022, American Journal of Transplantation.

[5]  H. Jessen,et al.  Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial , 2022, The Lancet Respiratory Medicine.

[6]  T. Welte,et al.  Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres , 2022, European Respiratory Journal.

[7]  E. Cohen,et al.  Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge , 2022, American Journal of Transplantation.

[8]  L. Riella,et al.  Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave , 2022, American Journal of Transplantation.

[9]  V. Lemée,et al.  Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients , 2022, Kidney International.

[10]  M. Pangalos,et al.  Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 , 2022, The New England journal of medicine.

[11]  D. Salerno,et al.  Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID‐19 in solid organ transplant recipients , 2022, American Journal of Transplantation.

[12]  M. Loebe,et al.  Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic , 2021, American Journal of Transplantation.

[13]  T. Kalina,et al.  Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein–specific T cells in Lung Transplant Recipients , 2021, Transplantation.

[14]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[15]  J. Fuge,et al.  COVID-19 in lung transplant recipients—Risk prediction and outcomes , 2021, PloS one.

[16]  T. Kalina,et al.  Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients , 2021, The Journal of Heart and Lung Transplantation.

[17]  F. Moreso,et al.  COVID-19 in transplant recipients: The Spanish experience , 2020, American Journal of Transplantation.

[18]  John D. Davis,et al.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[19]  F. D'Ovidio,et al.  COVID-19 in lung transplant recipients: A single center case series from New York City , 2020, American Journal of Transplantation.

[20]  M. Ison,et al.  COVID-19 in solid organ transplant: A multi-center cohort study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[22]  G. Verleden,et al.  Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.